Payment overview · 2025
General Payments
$113.92
5 reported records · 4 companies
Healthcare provider profile · identity verified
Tracy Higgins
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SHINGLETOWN, CA · NPI 1922726819
Verified facts
What the public records show
CMS Open Payments records show Tracy Higgins received $113.92 in general payments during 2025 across 5 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 36.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $41.86 | 36.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.22 | 23.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.29 | 22.2% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $20.55 | 18.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $113.92 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.22 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.22 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.29 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.29 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 231 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 187 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 172 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 169 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 44 |
| Lisinopril | Lisinopril | 99 | 34 |
| Trazodone Hcl | Trazodone Hcl | 99 | 17 |
| Baclofen | Baclofen | 90 | 16 |
| Omeprazole | Omeprazole | 88 | 33 |
| Metformin Hcl | Metformin Hcl | 87 | 27 |
| Ozempic | Semaglutide | 86 | 13 |
| Amlodipine Besylate | Amlodipine Besylate | 85 | 32 |
| Losartan Potassium | Losartan Potassium | 84 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 83 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 23 |
| Tramadol Hcl | Tramadol Hcl | 79 | 16 |
| Meloxicam | Meloxicam | 72 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 58 | 12 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 51 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 12 |
| Ibuprofen | Ibuprofen | 46 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Estradiol | Estradiol | 38 | 13 |
| Potassium Chloride | Potassium Chloride | 38 | suppressed |
| Furosemide | Furosemide | 37 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 11 |
| Sertraline Hcl | Sertraline Hcl | 34 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 15 |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 15 |
| Prednisone | Prednisone | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Carvedilol | Carvedilol | 24 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Abilify Maintena | Aripiprazole | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Fetzima | Levomilnacipran Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $113.92 · 5 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, ELIQUIS, NURTEC ODT, Ozempic, Rybelsus, SUBLOCADE, UZEDY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error